Oncology decision dossier
The treatment setting is the boundary. Evidence for first-line use, an FDA indication, and an NCCN listing are separate records. This dossier connects the published evidence history to the registered questions and the work their timing could affect.
For oncology market access, regulatory strategy, medical affairs, and payer reviewers.
Phase 1 of the record: registered before outcomes, registry snapshot , outcomes pending.
On July 2, 2025, FDA granted accelerated approval to sunvozertinib for adults with the specified EGFR exon 20 insertion mutation-positive, locally advanced or metastatic NSCLC whose disease had progressed on or after platinum chemotherapy. That later-line approval does not establish a first-line indication.
FDA: the July 2025 approval and its population.
The dated evidence ledger records the first-line trial report and institutional documents available to the assessment. Each entry identifies its source and date. The forecast records retain their own evidence cutoffs; later information does not rewrite them.
This page describes those records at their published cutoffs. For current approved use, consult the agency's current labeling. For guideline wording, consult the applicable NCCN version. Neither a frozen estimate nor its pending status establishes today's clinical recommendation or coverage.
These are related propositions with overlapping outcomes, not four independent therapy examples. Each record publishes its estimate, cutoff, baselines, and resolution rule. Calibration and useful lead time are not yet demonstrated.
Whether the NCCN first-line position changes by the registered deadline.
Cutoff · deadline · unresolved
Whether FDA approves the specified first-line indication by July 31, 2027.
Cutoff · deadline · unresolved
Whether the same action occurs by March 31, 2027. An April–July action would miss this deadline while potentially satisfying the July record.
Cutoff · deadline · unresolved
Whether FDA action precedes NCCN listing, with both occurring within the frozen window. This is a separate ordering question.
Cutoff · deadline · unresolved
The deadline is the last qualifying action date. The adjudication window can extend beyond it so an outcome can be checked. Read each frozen rule before comparing dates.
Illustrative planning scenarios: the dates below are forecast deadlines, not FDA commitments. An earlier decision compresses preparation; a later decision can justify resequencing work. Earlier notice of the same decision gives a team more time without changing the institutional date.
Patients may ultimately experience a difference in access, but an institutional forecast does not establish treatment suitability or a patient's coverage.
Guideline inclusion on rung 5 and regulatory action on rung 6 are distinct from payer action on rung 7. If NCCN moves first, review which policies reference that wording. If FDA moves first, compare the new indication with the guideline and policy already in force. Neither path establishes an automatic coverage change.
If one action does not occur by the deadline, retain that result. A later action does not retroactively satisfy an earlier deadline. The guide to delayed changes explains how to distinguish a procedural delay, a different action, and an unresolved reason.
Name the authority, the action, the population, and your deadline. Include what your team would prepare differently if the action occurred months earlier or later.
Start with one claim